Home・Aktien・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Open

BrancheGesundheitswesen

218.9 -0.11

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

214.8

Max

222.13

Schlüsselkennzahlen
By Trading Economics
Einkommen	20M 206M
Verkäufe	70M 1.2B
KGV Branchendurchschnitt	68.571 64.641
EPS	1.99
Gewinnspanne	17.649
Angestellte	2,500
EBITDA	159M 304M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+71.22% upside

Dividenden
By Acuity
Nächstes Ergebnis	29. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4B 37B
Vorheriger Eröffnungskurs	219.01
Vorheriger Schlusskurs	218.9

Nachrichtenstimmung

By Acuity

100%

320 / 340 Ranking in Healthcare

Alnylam Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Alnylam Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

71.22% Vorteil

12-Monats-Prognose

Durchschnitt 377.24 USD 71.22%

Hoch 550 USD

Tief 230 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alnylam Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Alnylam Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

320 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.